State programs normalize psilocybin therapy

State‑level regulatory programs and recent legalization are converting psilocybin from experimental treatment into routine, paid services: Oregon reported 5,935 clients in 2025, Colorado and New Mexico have established programs, and drugmakers are preparing FDA submissions. That confluence of patient numbers, state law, and imminent federal review signals rapid normalization and commercialization of psychedelic medicine. — Widespread, state-sanctioned use raises policy questions about access, clinical training, insurance coverage, criminal‑federal conflicts, and the pace at which experimental treatments scale into standard care.